Business context and reporting period
Quarterly report for the three and six months ended June 30, 2013. The filing identifies the registrant as On Assignment, Inc., a staffing provider focused on technology, healthcare, and life sciences; this differs from the request metadata naming Everforth Inc.
On Assignment reported five segments: Apex, Oxford, Life Sciences, Physician, and Healthcare. Comparisons are affected by the May 2012 acquisition of Apex, whose results were included for only six weeks in the 2012 comparison period. The Nurse Travel division was sold in February 2013 and is presented as discontinued operations.
Financial results and liquidity
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Revenue | $417.9 million | $265.9 million | $807.1 million | $422.6 million |
| Gross profit / margin | $124.6 million / 29.8% | $84.5 million / 31.8% | $237.8 million / 29.5% | $137.3 million / 32.5% |
| Operating income | $32.8 million | $15.5 million | $56.6 million | $24.9 million |
| Continuing operations income | $7.8 million | $6.1 million | $18.4 million | $11.1 million |
| Net income | $7.3 million | $7.6 million | $32.0 million | $12.9 million |
| Diluted EPS | $0.14 | $0.16 | $0.59 | $0.31 |
Q2 revenue increased 57.2%; management said pro forma growth, assuming Apex had been acquired at the start of the comparison period, was 15.4%. Six-month revenue rose 91.0%, with pro forma growth of 14.5%. The six-month 2013 net income includes a $14.4 million after-tax gain on the Nurse Travel sale; Q2 net income was also affected by a $15.0 million pretax write-off of old loan costs related to refinancing.
For the six months, operating cash flow was $30.3 million, versus cash used of $8.9 million in 2012. Investing cash flow was $22.7 million, including $31.9 million net proceeds from the Nurse Travel sale; capital expenditures were $7.3 million. Financing activities used $66.3 million, chiefly reflecting debt repayments and refinancing. Cash declined to $14.1 million from $27.5 million at year-end; $7.1 million was held abroad and management said it did not intend to repatriate it.
At June 30, 2013, total debt was $369.3 million, comprising $10.3 million current and $359.1 million long-term. Working capital was $174.8 million. The new $500 million credit facility had $122.5 million available; leverage was 2.30x against a 4.25x covenant limit, with the maximum stepping down to 3.25x by June 2015. The company reported covenant compliance. Management expected working capital, the facility, and operating cash flow to fund requirements for the next 12 months.
Material changes and management commentary
- Apex was the principal driver of reported growth. In Q2, Apex revenue was $233.4 million; Oxford revenue grew 15.2%, while the other three segments grew 3.4% to 7.0%.
- Overall gross margin contracted 200 basis points in Q2 and 300 basis points for the six months. Management attributed the decline principally to Apex’s lower-margin mix, faster growth in lower-margin services, and reduced permanent-placement and conversion-fee revenue. Segment-specific pressure also included Oxford’s reimbursable expenses and mix, Life Sciences’ lower retained-search fees and mix, and higher medical malpractice expense and mix in Physician.
- SG&A was $86.5 million in Q2 and $170.6 million for the six months; the increases primarily reflected Apex being included for more of each comparison period.
- The May 2013 refinancing replaced the prior facility with term A and B loans and a revolving facility. The early extinguishment resulted in the $15.0 million loan-cost write-off. Variable-rate debt exposure remains: management estimated a 1 percentage-point rate change would alter annual interest expense by about $3.4 million after considering swaps and caps.
- The filing describes an immaterial retrospective restatement of 2012 quarterly results for finalized Apex intangible-asset amortization and related taxes. It also describes a separate immaterial $0.5 million vendor-fee classification correction in 2012. Management stated neither affected annual consolidated net income, balance sheet, or cash flows where specified.
Outlook, risks, and contingencies
No quantified revenue or earnings guidance was provided. Management cited typical seasonality: staffing demand is usually lower in the first and fourth quarters and higher in the second and third quarters. Estimated 2013 capital expenditures were approximately $16 million. Potential acquisition earn-out payments were approximately $5.6 million through 2013, subject to performance targets.
Risks identified include economic-driven demand, recruiting and retaining consultants and contract professionals, competition for clients, growth management, information-system performance, medical malpractice and litigation matters, interest-rate exposure, and foreign-currency translation. The company is partially self-insured for workers’ compensation and medical malpractice; related reserves were $11.1 million. Management said pending legal matters were not expected to have a material effect based on facts then available. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is On Assignment, Inc.’s 2013 Form 10-Q, not a filing naming Everforth Inc.
- Assess sustainable growth and margins excluding Apex acquisition-period comparability effects and the Nurse Travel sale.
- Separate continuing-operations earnings from the sale gain and account for the refinancing-related loan-cost charge when assessing recurring earnings.
- Review debt terms, required amortization and excess-cash-flow prepayments, covenant headroom, and sensitivity to interest rates.
- Review the stated 2012 quarterly restatements and confirm the applicable figures in the company’s amended or subsequent filings.